Note 17 - Fair Value Disclosures (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At September 30, 2019:
Cash and cash equivalents	$	598	$	-	$	598	$	-	$	598
Other receivables	$	422,034	$	-	$	-	$	422,034	$	422,034
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	1,035,328	$	-	$	-	$	1,035,328	$	1,035,328
Loans payable	$	10,115,713	$	-	$	-	$	10,115,713	$	10,115,713
Loans payable - related parties	$	1,361,881	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,851,725	$	-	$	-	$	6,461,632	$	6,461,632
Convertible notes payable - related parties	$	2,558,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2018:
Cash and cash equivalents	$	3,193	$	-	$	3,193	$	-	$	3,193
Other receivables	$	418,905	$	-	$	-	$	418,905	$	418,905
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	875,328	$	-	$	-	$	875,328	$	875,328
Loans payable	$	10,107,205	$	-	$	-	$	10,107,205	$	10,107,205
Loans payable - related parties	$	1,360,806	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,143,647	$	-	$	-	$	5,534,810	$	5,534,810
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-